Bright Minds Biosciences Inc. (DRUG)
NASDAQ: DRUG · Real-Time Price · USD
27.76
+0.20 (0.74%)
Jun 5, 2025, 12:00 PM - Market open

Bright Minds Biosciences Statistics

Total Valuation

DRUG has a market cap or net worth of $198.09 million. The enterprise value is $157.63 million.

Market Cap 198.09M
Enterprise Value 157.63M

Important Dates

The last earnings date was Thursday, May 15, 2025, before market open.

Earnings Date May 15, 2025
Ex-Dividend Date n/a

Share Statistics

DRUG has 7.08 million shares outstanding. The number of shares has increased by 39.99% in one year.

Current Share Class 7.08M
Shares Outstanding 7.08M
Shares Change (YoY) +39.99%
Shares Change (QoQ) +5.97%
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float 2.98M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 5.11
P/TBV Ratio 5.11
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 88.27, with a Debt / Equity ratio of 0.00.

Current Ratio 88.27
Quick Ratio 87.64
Debt / Equity 0.00
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -183.80

Financial Efficiency

Return on equity (ROE) is -11.21% and return on invested capital (ROIC) is -10.80%.

Return on Equity (ROE) -11.21%
Return on Assets (ROA) -10.57%
Return on Invested Capital (ROIC) -10.80%
Return on Capital Employed (ROCE) -9.54%
Revenue Per Employee n/a
Profits Per Employee n/a
Employee Count n/a
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +2,250.43% in the last 52 weeks. The beta is 1.19, so DRUG's price volatility has been higher than the market average.

Beta (5Y) 1.19
52-Week Price Change +2,250.43%
50-Day Moving Average 31.37
200-Day Moving Average 29.54
Relative Strength Index (RSI) 39.65
Average Volume (20 Days) 29,490

Short Selling Information

The latest short interest is 80,327, so 1.13% of the outstanding shares have been sold short.

Short Interest 80,327
Short Previous Month 86,838
Short % of Shares Out 1.13%
Short % of Float 2.69%
Short Ratio (days to cover) 2.85

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -3.71M
Pretax Income -3.82M
Net Income -2.40M
EBITDA n/a
EBIT -3.71M
Earnings Per Share (EPS) -$0.44
Full Income Statement

Balance Sheet

The company has $38.74 million in cash and $115,905 in debt, giving a net cash position of $38.62 million or $5.45 per share.

Cash & Cash Equivalents 38.74M
Total Debt 115,905
Net Cash 38.62M
Net Cash Per Share $5.45
Equity (Book Value) 38.78M
Book Value Per Share 5.48
Working Capital 38.74M
Full Balance Sheet

Cash Flow

Operating Cash Flow -2.88M
Capital Expenditures n/a
Free Cash Flow n/a
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

DRUG does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -39.99%
Shareholder Yield -39.99%
Earnings Yield -1.21%
FCF Yield n/a

Analyst Forecast

The average price target for DRUG is $83.25, which is 199.95% higher than the current price. The consensus rating is "Strong Buy".

Price Target $83.25
Price Target Difference 199.95%
Analyst Consensus Strong Buy
Analyst Count 6
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on July 14, 2023. It was a reverse split with a ratio of 0.2:1.

Last Split Date Jul 14, 2023
Split Type Reverse
Split Ratio 0.2:1

Scores

Altman Z-Score n/a
Piotroski F-Score 1